🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million new cases each year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the face of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, also known as a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This approval marks a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin eradicated more than 90% of cases of the STI. This places it at an comparable level with the existing first-line therapy, which uses two antibiotics. The research enrolled hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Clinicians treating patients have shared hope. Access to a one-pill regimen like this is described as a "game-changer" for managing the epidemic. This is deemed vital to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.